Triclabendazole (Anthelmintic Drug) Effects on the Excretory- Secretory Proteome of Fasciola hepatica in Two Dimension Electrophoresis Gel.
AbstractBackground: The aim of this study was to evaluate the protein spots of excre-tory - secretory products of Fasciola hepatica using two dimension electrophoresis method in the presence and absence of triclabendazole drug which can be consid-ered to detect the target protein of the drug.Methods: F. hepatica parasites were collected from infected cattle livers, divided in two groups and cultivated in RPMI 1640 medium. First group was treated with triclabendazole (TCBZ) and second group considered as control. The excretory-secretory (ES) products of each group were separated and total protein deter-mined by Bradford method. To provide proteome spots, the ES proteins were precipitated and two dimension electrophoresis (2-DE) gel prepared. Protein amounts of two groups were compared using the statistical t-test and protein spots from 2-DE in test and control groups were also statistically analyzed. The protein spots of gels were identified by using protein database.Results: The t-test showed a significant increase of total proteins in treated group (P<0.5). The protein spots count in the control group was less than test group however statistically not significant (p>0.05). Cathepsin L- protein (MW 36.7 pH 5.34), 14-3-3 epsilon 2 isoform (MW 28.2 pH 5.36), Cathepsin L1D (MW 36.5 pH 5.8) and Cathepsin L1D (MW 36.6 pH 6.26) were identified in test group.Conclusion: It seems that, these results can be considered to determine the pro-teins which the drug acts as a target on them.
Rokni MB. The present status of human helmin-thic diseases in Iran. Ann J Trop Med Parasitol. 2008; 102(4):283–95.
Andrews SJ. The life-cycle of Fasciola hepatica. In: Dalton JP, ed. Fasciolosis CABI: Oxford, United Kingdom. pp. 1–29; 1999.
Moghaddam AS, Massoud J, Mahmoodi M, Mahvi AH, Periago M V, Artigas P, et al. Human and animal fascioliasis in Mazandaran province, northern Iran. Parasitol Res. 2004; 94(1):61–9.
Villegas F, Angles R, Barrientos R, Barrios G, Valero MA, Hamed K, et al. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bo-livian Altiplano. Plos Neg Trop Dis. 2012; 6(8):1720.
Cervi, L.; Serradell, M.C.; Guasconi, L. & Masih, D.T. New insights into the modulation of im-mune response by Fasciola hepatica excretory-secretory products. Current Immunology Re-views. (2009); .5(4): 277-284.
Issaq HJ, Veenstra TD. Two-dimensional poly-acrylamide gel electrophoresis (2D-PAGE): ad-vances and perspectives. Biotechniques. 2008; 44(5):697.
Jefferies JR, Campbell AM, Rossum AJ van, Bar-rett J, Brophy PM. Proteomic analysis of Fasciola hepatica excretory‐secretory products. Proteomics. 2001; 1(9):1128–32.
Maizels R M, Blaxter M L, Robertson B D, Sel-kirk M E. Parasite antigen parasite genes, first published, Combridge University Press, 1991.
Toner E, Brennan GP, Hanna REB, Edgar HW, Fairweather I. Tegumental surface changes in adult Fasciola hepatica in response to treatment in vivo with triclabendazole in the sheep host. Vet Parasitol. 2010; 172(3):238–48.
Stitt AW, Fairweather I. The effect of sulphoxide metabolite of triclabendazole (’Fasinex') on the tegument of mature and immature stages of the liver fluke, Fasciola hepatica. Parasitology. 1994;108:555.
Gourbal BEF, Guillou F, Mitta G, Sibille P, Thèron A, Pointier J-P, et al. Excretory–secretory products of larval Fasciola hepatica investigated us-ing a two-dimensional proteomic approach. Mol Biochem Parasit. 2008; 161(1):63–6.
Morphew RM, Wright HA, LaCourse EJ, Woods DJ, Brophy PM. Comparative proteomics of ex-cretory-secretory proteins released by the liver fluke Fasciola hepatica in sheep host bile and during in vitro culture ex host. Mol Cell Proteomics. 2007; 6(6):963–72.